Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more
Jeil Pharmaceutical Co Ltd (271980) - Total Liabilities
Latest total liabilities as of September 2025: ₩258.07 Billion KRW
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has total liabilities worth ₩258.07 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jeil Pharmaceutical Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jeil Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Impiana Hotels Bhd
KLSE:7243
|
Malaysia | RM205.06 Million |
|
CrystalGenomics Inc
KQ:083790
|
Korea | ₩124.24 Billion |
|
Ideal Finansal Teknolojiler ve Danismanlik Anonim Sirketi
IS:SKYLP
|
Turkey | TL22.96 Million |
|
Taiwan Steel Union Co Ltd
TW:6581
|
Taiwan | NT$818.73 Million |
|
Vecima Networks Inc
PINK:VNWTF
|
USA | $117.92 Million |
|
Aura Energy Ltd
AU:AEE
|
Australia | AU$2.36 Million |
|
The Klinique Med Clinic PCL
BK:KLINIQ
|
Thailand | ฿1.43 Billion |
|
UEM Edgenta Bhd
KLSE:1368
|
Malaysia | RM1.34 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Jeil Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jeil Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jeil Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total liabilities of Jeil Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩306.38 Billion | -7.24% |
| 2023-12-31 | ₩330.29 Billion | +9.63% |
| 2022-12-31 | ₩301.29 Billion | +16.27% |
| 2021-12-31 | ₩259.14 Billion | +9.26% |
| 2020-12-31 | ₩237.18 Billion | +2.44% |
| 2019-12-31 | ₩231.54 Billion | +6.23% |
| 2018-12-31 | ₩217.97 Billion | -7.54% |
| 2017-12-31 | ₩235.74 Billion | -- |